{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-130432","form_type":"8-K","ticker":"INAB","cik":"0001740279","company_name":"IN8BIO, INC.","filed_at":"2023-05-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.335082+00:00","generated_at":"2026-06-16T05:10:26.551590+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"high","headline":"IN8bio appoints Jeremy Graff, Ph.D. as Class I director","bullets":["Board expanded from six to seven directors; Graff appointed effective May 1, 2023, term expiring at 2025 annual meeting.","Graff currently serves as Chief Scientific Officer of IMV, Inc.; previously President/CSO of Biothera Pharmaceuticals and Chief Development Officer at HiberCell.","Graff will serve on Nominating & Corporate Governance Committee and chair the Science and Technology Committee.","Compensation follows standard non-employee director policy; company entered into standard indemnification agreement with Graff."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-130432","json":"https://secwatch.observer/filing/0001193125-23-130432.json","markdown":"https://secwatch.observer/filing/0001193125-23-130432.md","text":"https://secwatch.observer/filing/0001193125-23-130432.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1740279/000119312523130432/0001193125-23-130432-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1740279/000119312523130432/d467270d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-16T05:10:26.551590+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"38bbc30705","claim":"Jeremy Graff, Ph.D. was appointed as Class I director at IN8BIO, INC..","evidence_excerpt":"appointed Jeremy Graff, Ph.D., as a Class I director of the Company","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1740279/000119312523130432/0001193125-23-130432-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Class I director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}